ENTYCE® (capromorelin oral solution), the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking ghrelin (the "hunger hormone"). Administered orally once a day, ENTYCE is appropriate to treat inappetence caused by chronic and acute conditions.
Entyce is a selective ghrelin receptor agonist that binds to receptors that stimulate appetite. A laboratory study conducted with Entyce showed an increased appetite in normal healthy dogs. In a clinical trial, Entyce was proven effective in dogs with a reduced or no appetite due to various underlying medical conditions. Good appetite and nutrition help support overall health and are important factors a veterinarian considers when managing disease conditions in dogs. The side effects of Entyce include diarrhea, vomiting, increased thirst, and increased salivation. The drug should be used with caution in dogs with liver or kidney problems.
Entyce must be prescribed by a licensed veterinarian because professional expertise is needed to diagnose and manage decreased appetite in dogs and to monitor patients for possible adverse effects of the drug.
ENTYCE® (capromorelin oral solution) is a ghrelin receptor agonist that mimics the effect of ghrelin (the "hunger hormone"). Like naturally occurring ghrelin, ENTYCE binds to specific cell receptors and affects signaling in the hypothalamus, causing the feeling of hunger.